Tag: Cancer: Bladder

Patients in the single-port versus multiport system group reported better cosmetic appearance, higher satisfaction with cosmetic appearance of surgical scar

Authors say Gem/Doce warrants further study for the treatment of BCG-naive high-risk non-muscle-invasive bladder cancer

For patients treated with adequate BCG, risk for BCG unresponsiveness, progression similar for all high-grade Ta tumors

Number of days alive and out of hospital within first 90 days greater for robot-assisted surgery, but clinical significance of findings unclear

Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo

Changes, delays, and cancellation of cancer treatment and ancillary care reported

No difference seen in percentage of patients recovering at each time point for robot-assisted versus open radical cystectomy

Trial involving seven patients with locally advanced bladder cancer shows concurrent CON with radiation therapy feasible in Australia

Disease-free survival was longer with adjuvant nivolumab in intention-to-treat population, for those with PD-L1 expression at least 1 percent

Overall survival longer compared with standard chemo for disease progression following platinum-based chemo and PD-1 or PD-L1 inhibitor